PCLOF (PharmaCielo) Pretax Margin %: 67.20% (As of Dec. 2025)


What is PharmaCielo Pretax Margin %?

PharmaCielo PCLOF -4.35% Pretax Margin % is 67.20% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, PharmaCielo ranks worse than 91.83% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. PharmaCielo's Pre-Tax Income for the three months ended in Dec. 2025 was $0.30 Mil. PharmaCielo's Revenue for the three months ended in Dec. 2025 was $0.44 Mil. Therefore, PharmaCielo's pretax margin for the quarter that ended in Dec. 2025 was 67.20%.

The historical rank and industry rank for PharmaCielo's Pretax Margin % or its related term are showing as below:

PCLOF' s Pretax Margin % Range Over the Past 10 Years
Min: -4404.96   Med: -1369.15   Max: -125.41
Current: -125.41


PCLOF's Pretax Margin % is ranked worse than
91.83% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.28 vs PCLOF: -125.41

PharmaCielo  (OTCPK:PCLOF) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


PharmaCielo Pretax Margin % Related Terms


PharmaCielo Pretax Margin % Historical Data

* Premium members only.

The historical data trend for PharmaCielo's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCielo Pretax Margin % Chart

PharmaCielo Annual Data
Trend Aug17 Aug18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial -4,402.17 -1,648.65 -1,368.75 -273.41 -1,057.27

PharmaCielo Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -198.98 -133.38 -403.39 -155.83 67.20

PCLOF vs ZTS: Pretax Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCielo Pretax Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where PharmaCielo's Pretax Margin % falls into.



PharmaCielo Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

PharmaCielo's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-12.148/1.149
=-1,057.27 %

PharmaCielo's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0.295/0.439
=67.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of 67.20% mean?
PharmaCielo (PCLOF) has a Pretax Margin % of 67.20% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PharmaCielo and its competitors. According to the industry distribution chart, PharmaCielo ranks #877 out of 955 companies in the Drug Manufacturers industry, placing it in the top 91.8%.
Is PharmaCielo's Pretax Margin % too high?
PharmaCielo's current Pretax Margin % is 67.20%. The Drug Manufacturers industry median Pretax Margin % is 7.28. PharmaCielo's value of 67.20% is 823.1% above this industry median. Based on the distribution chart, PharmaCielo ranks #877 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #877 out of 955 companies for Pretax Margin %. This places PharmaCielo in the lower half of its industry. The industry median Pretax Margin % is 7.28. PharmaCielo's value of 67.20% is 823.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current Pretax Margin % of 67.20% is 823.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current Pretax Margin % is 67.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.05 — trading 48.5% below its estimated fair value. The current Pretax Margin % is 67.20% and 823.1% above the Drug Manufacturers industry median of 7.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Pretax Margin % is 67.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.